RxDoctor Payments Data

Amarjeet Sethi, MD

Pulmonary Disease · Waterford, MINPI 1467415034

Payments from drug & device makers

$1,703in general payments, 2019–2025

Across 85 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$631
  • Insmed, Inc.$194
  • AstraZeneca$190
  • Mylan Specialty L.p.$129
  • Intuitive Surgical$94
  • Boehringer Ingelheim$89
  • plus $378 from 10 others

What the payments were for

  • Food & beverage$1,64797%
  • Education$563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,703 in reported general payments places this provider in the 45th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$237,157
Medicare patients
562
Services billed
2,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate56$733,388
Trelegy ElliptaFluticasone/Umeclidin/Vilanter586$521,877
Breztri AerosphereBudesonide/Glycopyr/Formoterol71$64,184
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$16,297
Breo ElliptaFluticasone/Vilanterol18$11,471
Ventolin HfaAlbuterol Sulfate121$9,664
Combivent RespimatIpratropium/Albuterol Sulfate12$8,964
Albuterol Sulfate HfaAlbuterol Sulfate221$8,557
SymbicortBudesonide/Formoterol Fumarate21$7,587
DuleraMometasone/Formoterol20$6,757
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$6,586
Incruse ElliptaUmeclidinium Bromide15$5,326
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$3,844
Montelukast Sodium248$3,169
Roflumilast13$1,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Combivent Respimat$89$742,35268 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$631$554,971649 claims
AstraZenecaBreztri Aerosphere, Symbicort$190$71,77192 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Waterford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →